Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model.

Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, Bermúdez González MC, Leyva-Grado VH, Evans MJ, Simon V, Lim JK, Krammer F, Hai R, Palese P, Tan GS.

Nat Commun. 2018 Nov 1;9(1):4560. doi: 10.1038/s41467-018-07008-0.

2.

Antibody responses towards the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets and humans.

Sun W, Kang DS, Zheng A, Liu STH, Broecker F, Simon V, Krammer F, Palese P.

J Virol. 2018 Oct 31. pii: JVI.01673-18. doi: 10.1128/JVI.01673-18. [Epub ahead of print]

PMID:
30381487
3.

Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance.

Liu STH, Behzadi MA, Sun W, Freyn AW, Liu WC, Broecker F, Albrecht RA, Bouvier NM, Simon V, Nachbagauer R, Krammer F, Palese P.

J Clin Invest. 2018 Nov 1;128(11):4992-4996. doi: 10.1172/JCI122895. Epub 2018 Oct 8.

4.

Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.

Broecker F, Liu STH, Sun W, Krammer F, Simon V, Palese P.

J Virol. 2018 Sep 26;92(20). pii: e01100-18. doi: 10.1128/JVI.01100-18. Print 2018 Oct 15.

PMID:
30045991
5.

Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine.

Coughlan L, Palese P.

Cell Host Microbe. 2018 Jul 11;24(1):18-24. doi: 10.1016/j.chom.2018.06.016. Review.

PMID:
30001520
6.

Influenza.

Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, García-Sastre A.

Nat Rev Dis Primers. 2018 Jun 28;4(1):3. doi: 10.1038/s41572-018-0002-y. Review. No abstract available.

PMID:
29955068
7.

The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus.

Fulton BO, Sun W, Heaton NS, Palese P.

J Virol. 2018 Jul 31;92(16). pii: e00754-18. doi: 10.1128/JVI.00754-18. Print 2018 Aug 15.

PMID:
29899093
8.

Development of next generation hemagglutinin-based broadly protective influenza virus vaccines.

Nachbagauer R, Palese P.

Curr Opin Immunol. 2018 Aug;53:51-57. doi: 10.1016/j.coi.2018.04.001. Epub 2018 Apr 20. Review.

PMID:
29680576
9.

An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations.

Rajendran M, Sun W, Comella P, Nachbagauer R, Wohlbold TJ, Amanat F, Kirkpatrick E, Palese P, Krammer F.

PLoS One. 2018 Apr 4;13(4):e0194830. doi: 10.1371/journal.pone.0194830. eCollection 2018.

10.

A Recombinant Antibody-Expressing Influenza Virus Delays Tumor Growth in a Mouse Model.

Hamilton JR, Vijayakumar G, Palese P.

Cell Rep. 2018 Jan 2;22(1):1-7. doi: 10.1016/j.celrep.2017.12.025.

11.

A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.

Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, Solórzano A, Berlanda-Scorza F, García-Sastre A, Palese P, Albrecht RA, Krammer F.

NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017.

12.

Influenza: A broadly protective antibody.

Palese P.

Nature. 2017 Nov 15;551(7680):310-311. doi: 10.1038/551310a. No abstract available.

PMID:
29144466
13.

Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice.

He W, Chen CJ, Mullarkey CE, Hamilton JR, Wong CK, Leon PE, Uccellini MB, Chromikova V, Henry C, Hoffman KW, Lim JK, Wilson PC, Miller MS, Krammer F, Palese P, Tan GS.

Nat Commun. 2017 Oct 10;8(1):846. doi: 10.1038/s41467-017-00928-3.

14.

Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model.

Jacobsen H, Rajendran M, Choi A, Sjursen H, Brokstad KA, Cox RJ, Palese P, Krammer F, Nachbagauer R.

MBio. 2017 Sep 19;8(5). pii: e01463-17. doi: 10.1128/mBio.01463-17.

15.

Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization.

Maamary J, Wang TT, Tan GS, Palese P, Ravetch JV.

Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10172-10177. doi: 10.1073/pnas.1707950114. Epub 2017 Sep 5.

16.

Broadly protective murine monoclonal antibodies against influenza B virus target highly conserved neuraminidase epitopes.

Wohlbold TJ, Podolsky KA, Chromikova V, Kirkpatrick E, Falconieri V, Meade P, Amanat F, Tan J, tenOever BR, Tan GS, Subramaniam S, Palese P, Krammer F.

Nat Microbiol. 2017 Oct;2(10):1415-1424. doi: 10.1038/s41564-017-0011-8. Epub 2017 Aug 21.

17.

Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.

Goff PH, Hayashi T, He W, Yao S, Cottam HB, Tan GS, Crain B, Krammer F, Messer K, Pu M, Carson DA, Palese P, Corr M.

J Virol. 2017 Sep 12;91(19). pii: e01050-17. doi: 10.1128/JVI.01050-17. Print 2017 Oct 1.

18.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine.

Krammer F, García-Sastre A, Palese P.

Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7). pii: a028845. doi: 10.1101/cshperspect.a028845. Review.

PMID:
28663209
19.

Transposon Mutagenesis of the Zika Virus Genome Highlights Regions Essential for RNA Replication and Restricted for Immune Evasion.

Fulton BO, Sachs D, Schwarz MC, Palese P, Evans MJ.

J Virol. 2017 Jul 12;91(15). pii: e00698-17. doi: 10.1128/JVI.00698-17. Print 2017 Aug 1.

20.

Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model.

Ermler ME, Kirkpatrick E, Sun W, Hai R, Amanat F, Chromikova V, Palese P, Krammer F.

J Virol. 2017 May 26;91(12). pii: e00286-17. doi: 10.1128/JVI.00286-17. Print 2017 Jun 15.

21.

Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

Rajendran M, Nachbagauer R, Ermler ME, Bunduc P, Amanat F, Izikson R, Cox M, Palese P, Eichelberger M, Krammer F.

MBio. 2017 Mar 21;8(2). pii: e02281-16. doi: 10.1128/mBio.02281-16.

22.

Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.

Leyva-Grado VH, Palese P.

Antiviral Res. 2017 Jun;142:12-15. doi: 10.1016/j.antiviral.2017.03.002. Epub 2017 Mar 7.

23.

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP.

Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340.

24.

Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins.

Nachbagauer R, Choi A, Hirsh A, Margine I, Iida S, Barrera A, Ferres M, Albrecht RA, García-Sastre A, Bouvier NM, Ito K, Medina RA, Palese P, Krammer F.

Nat Immunol. 2017 Apr;18(4):464-473. doi: 10.1038/ni.3684. Epub 2017 Feb 13.

25.

Profile of Charles M. Rice, Ralf F. W. Bartenschlager, and Michael J. Sofia, 2016 Lasker-DeBakey Clinical Medical Research Awardees.

Palese P.

Proc Natl Acad Sci U S A. 2016 Dec 6;113(49):13934-13937. Epub 2016 Nov 18. No abstract available.

26.

Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus.

He W, Tan GS, Mullarkey CE, Lee AJ, Lam MM, Krammer F, Henry C, Wilson PC, Ashkar AA, Palese P, Miller MS.

Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11931-11936. Epub 2016 Oct 3.

27.

Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.

Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P.

MBio. 2016 Oct 4;7(5). pii: e01624-16. doi: 10.1128/mBio.01624-16.

28.

Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.

Leon PE, He W, Mullarkey CE, Bailey MJ, Miller MS, Krammer F, Palese P, Tan GS.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5944-E5951. Epub 2016 Sep 19.

29.

Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection.

Henry Dunand CJ, Leon PE, Huang M, Choi A, Chromikova V, Ho IY, Tan GS, Cruz J, Hirsh A, Zheng NY, Mullarkey CE, Ennis FA, Terajima M, Treanor JJ, Topham DJ, Subbarao K, Palese P, Krammer F, Wilson PC.

Cell Host Microbe. 2016 Jun 8;19(6):800-13. doi: 10.1016/j.chom.2016.05.014.

30.

Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate.

Tran EE, Podolsky KA, Bartesaghi A, Kuybeda O, Grandinetti G, Wohlbold TJ, Tan GS, Nachbagauer R, Palese P, Krammer F, Subramaniam S.

MBio. 2016 Mar 22;7(2):e00257. doi: 10.1128/mBio.00257-16.

31.

Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity.

Hamilton JR, Sachs D, Lim JK, Langlois RA, Palese P, Heaton NS.

Proc Natl Acad Sci U S A. 2016 Apr 5;113(14):3861-6. doi: 10.1073/pnas.1522376113. Epub 2016 Mar 21.

32.

Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection.

Heaton NS, Moshkina N, Fenouil R, Gardner TJ, Aguirre S, Shah PS, Zhao N, Manganaro L, Hultquist JF, Noel J, Sachs D, Hamilton J, Leon PE, Chawdury A, Tripathi S, Melegari C, Campisi L, Hai R, Metreveli G, Gamarnik AV, García-Sastre A, Greenbaum B, Simon V, Fernandez-Sesma A, Krogan NJ, Mulder LCF, van Bakel H, Tortorella D, Taunton J, Palese P, Marazzi I.

Immunity. 2016 Jan 19;44(1):46-58. doi: 10.1016/j.immuni.2015.12.017. Erratum in: Immunity. 2016 Feb 16;44(2):438. Sachs, David H [corrected to Sachs, David].

33.

Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans.

Nachbagauer R, Choi A, Izikson R, Cox MM, Palese P, Krammer F.

MBio. 2016 Jan 19;7(1):e01996-15. doi: 10.1128/mBio.01996-15.

34.

Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins.

Chen CJ, Ermler ME, Tan GS, Krammer F, Palese P, Hai R.

J Virol. 2016 Jan 13;90(7):3789-93. doi: 10.1128/JVI.03060-15.

35.

Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.

DiLillo DJ, Palese P, Wilson PC, Ravetch JV.

J Clin Invest. 2016 Feb;126(2):605-10. doi: 10.1172/JCI84428. Epub 2016 Jan 5.

36.

Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets.

Nachbagauer R, Miller MS, Hai R, Ryder AB, Rose JK, Palese P, García-Sastre A, Krammer F, Albrecht RA.

J Virol. 2015 Dec 30;90(6):3268-73. doi: 10.1128/JVI.02481-15.

37.

A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice.

Nachbagauer R, Kinzler D, Choi A, Hirsh A, Beaulieu E, Lecrenier N, Innis BL, Palese P, Mallett CP, Krammer F.

NPJ Vaccines. 2016;1. pii: 16015. doi: 10.1038/npjvaccines.2016.15. Epub 2016 Sep 22.

38.

Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.

Ryder AB, Nachbagauer R, Buonocore L, Palese P, Krammer F, Rose JK.

J Virol. 2015 Dec 16;90(5):2544-50. doi: 10.1128/JVI.02598-15.

39.

Immune history profoundly affects broadly protective B cell responses to influenza.

Andrews SF, Huang Y, Kaur K, Popova LI, Ho IY, Pauli NT, Henry Dunand CJ, Taylor WM, Lim S, Huang M, Qu X, Lee JH, Salgado-Ferrer M, Krammer F, Palese P, Wrammert J, Ahmed R, Wilson PC.

Sci Transl Med. 2015 Dec 2;7(316):316ra192. doi: 10.1126/scitranslmed.aad0522.

40.

Replication-Competent Influenza B Reporter Viruses as Tools for Screening Antivirals and Antibodies.

Fulton BO, Palese P, Heaton NS.

J Virol. 2015 Dec;89(23):12226-31. doi: 10.1128/JVI.02164-15. Epub 2015 Sep 23.

41.

In memoriam--Richard M. Elliott (1954-2015).

Brennan B, Weber F, Kormelink R, Schnettler E, Bouloy M, Failloux AB, Weaver SC, Fazakerley JK, Fragkoudis R, Harris M, Barr JN, Palese P, García-Sastre A, Dalziel RG, Dutia BM, Lowen AC, Steel J, Randall RE, Paul Duprex W, Rice CM, Tesh RB, Murphy FA, Ebihara H, Vasconcelos PF, Nunes MR, Fooks AR, Smith GL, Goodfellow I, Pappu HR, Lamb RA, Paterson RG, Higgs S, Vanlandingham DL, Dietzgen RG, Stephen Lodmell J, Nichol ST, Daly J, Ullman DE, Plyusnin A, Plyusnina A, Efstathiou S, Hewson R, Tordo N, Cherry S, Boutell C, Hosie MJ, Murcia PR, Neil JC, Palmarini M, Patel AH, Willett BJ, Kohl A, McLauchlan J.

J Gen Virol. 2015 Aug;96(8):1975-8. doi: 10.1099/jgv.0.000241. No abstract available.

42.

Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy.

Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, Schlesinger SJ, Palese P, Ahmed R, Ravetch JV.

Cell. 2015 Jul 2;162(1):160-9. doi: 10.1016/j.cell.2015.06.026.

43.

Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins.

Fulton BO, Sachs D, Beaty SM, Won ST, Lee B, Palese P, Heaton NS.

Cell Rep. 2015 Jun 9;11(9):1331-8. doi: 10.1016/j.celrep.2015.04.054. Epub 2015 May 21.

44.

A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein.

White KM, De Jesus P, Chen Z, Abreu P Jr, Barile E, Mak PA, Anderson P, Nguyen QT, Inoue A, Stertz S, Koenig R, Pellecchia M, Palese P, Kuhen K, García-Sastre A, Chanda SK, Shaw ML.

ACS Infect Dis. 2015 Feb 13;1(2):98-109. Epub 2014 Dec 15.

45.

High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

Kaur K, Zheng NY, Smith K, Huang M, Li L, Pauli NT, Henry Dunand CJ, Lee JH, Morrissey M, Wu Y, Joachims ML, Munroe ME, Lau D, Qu X, Krammer F, Wrammert J, Palese P, Ahmed R, James JA, Wilson PC.

PLoS One. 2015 May 7;10(5):e0125618. doi: 10.1371/journal.pone.0125618. eCollection 2015.

46.

Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies.

Leyva-Grado VH, Tan GS, Leon PE, Yondola M, Palese P.

Antimicrob Agents Chemother. 2015 Jul;59(7):4162-72. doi: 10.1128/AAC.00290-15. Epub 2015 May 4.

47.

Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice.

Wohlbold TJ, Nachbagauer R, Xu H, Tan GS, Hirsh A, Brokstad KA, Cox RJ, Palese P, Krammer F.

MBio. 2015 Mar 10;6(2):e02556. doi: 10.1128/mBio.02556-14.

48.

Advances in the development of influenza virus vaccines.

Krammer F, Palese P.

Nat Rev Drug Discov. 2015 Mar;14(3):167-82. doi: 10.1038/nrd4529. Review. Erratum in: Nat Rev Drug Discov. 2015 Apr;14(4):294.

PMID:
25722244
49.

Preexisting human antibodies neutralize recently emerged H7N9 influenza strains.

Henry Dunand CJ, Leon PE, Kaur K, Tan GS, Zheng NY, Andrews S, Huang M, Qu X, Huang Y, Salgado-Ferrer M, Ho IY, Taylor W, Hai R, Wrammert J, Ahmed R, García-Sastre A, Palese P, Krammer F, Wilson PC.

J Clin Invest. 2015 Mar 2;125(3):1255-68. doi: 10.1172/JCI74374. Epub 2015 Feb 17.

50.

Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.

He W, Mullarkey CE, Duty JA, Moran TM, Palese P, Miller MS.

J Virol. 2015 Apr;89(7):3610-8. doi: 10.1128/JVI.03099-14. Epub 2015 Jan 14.

Supplemental Content

Loading ...
Support Center